A man suspected in the theft of a $6,000 engagement ring and other items in Woodbridge is facing multiple criminal charges after police caught him leaving the scene of a burglary in Plainfield three days later, authorities said this week.
Thomas Deschaine, 23, of the Avenel section of Woodbridge is facing charges of burglary, possession of drug paraphernalia and possession of a hypodermic needle in connection with the drug incident, said Plainfield Police Detective Leslie Hudson, who is investigating the case. Bail for Deschaine was set at $25,000; he was lodged in Union County Jail earlier this week, but on Wednesday was awaiting transfer back to Plainfield to be booked on an additional charge of credit-card theft filed in connection with the earlier incident, authorities said.
A Woodbridge police officer last Thursday was dispatched to the Verizon Wireless store at Woodbridge Center Mall on a report of theft. The officer met a 27-year-old Piscataway woman, an employee of the store, who said someone had taken several items from her purse the day before, according to a police report.
The woman said she had placed her purse in her unlocked employee locker at the start of her shift, but after work noticed that her BlackBerry cellphone had been moved from one pocket to another, the report indicated. The victim initially didn’t think anything of it, but the next day she found that her debit card, her engagement ring, a white gold necklace and her Verizon employee Android Incredible cell phone all were missing from the purse, according to the report.
An investigation revealed that a four-person construction crew was working in the store’s locker area at the time of the alleged theft, but all four workers — Deschaine being among them — denied involvement, authorities said. Deschaine and another worker also claimed to have seen a Verizon cleaning employee in the area sometime that night, the report indicated.
No charges were filed then, but Plainfield police responding to an alarm on the 1200 block of Thornton Avenue a little after 7:30 p.m. on Saturday found that a home had been broken into and a television taken, authorities said.
2011年8月28日星期日
2011年8月8日星期一
Once the concerns are heard
Michelle Stevens said she plans to attend the meeting and do whatever is necessary to help get this C.O.P. off the ground.
Stevens, who has lived in the neighborhood 10 years, said the area has seen a rash of car break-ins and more obvious signs of drug use.
At the end of July, she found a used hypodermic needle on the ground.
"I think the dynamics of the neighborhood change a lot, depending on renters and how the housing market is doing," said Stevens, 37. "We have trending problems. The drug activity, I didn't realize we had."
The neighborhood is a victim of geography.
The line that separates city from county runs through the neighborhood, often making it difficult for police to determine if an incident is within their jurisdiction, Christian said.
To make sure the communication channel is clear, Christian contacted Baltimore County and city police for next week's meeting, in addition to 1st District Councilman Tom Quirk, from the county; and 8th District Councilwoman Helen Holton, from the city.
"Nobody knows if we're city or county," said Christian, who lives on Medwick Garth East. "Both parties need to be helpful here. It can't be just one or the other."
Christian admitted he is at the head of this project despite knowing that he and his wife, Michelle, may not be residents of the community much longer.
A student in the College of Notre Dame of Maryland's Leadership in Teaching master's degree program, Christian is unsure of where he will end up next.
Once the C.O.P. gets off the ground, Christian said he wants to hear the concerns of his neighbors.
"We know more or less what the problems are, but I know there are people in this community that want to say something," said Christian, a Spanish teacher at Our Lady of Good Counsel in Baltimore.
Once the concerns are heard, Christian said the group will begin assigning roles and assigning areas of responsibility.
"It's an immediate demand for the community," Christian said.
"We feel like our neighborhood is something worth defending."
Stevens, who has lived in the neighborhood 10 years, said the area has seen a rash of car break-ins and more obvious signs of drug use.
At the end of July, she found a used hypodermic needle on the ground.
"I think the dynamics of the neighborhood change a lot, depending on renters and how the housing market is doing," said Stevens, 37. "We have trending problems. The drug activity, I didn't realize we had."
The neighborhood is a victim of geography.
The line that separates city from county runs through the neighborhood, often making it difficult for police to determine if an incident is within their jurisdiction, Christian said.
To make sure the communication channel is clear, Christian contacted Baltimore County and city police for next week's meeting, in addition to 1st District Councilman Tom Quirk, from the county; and 8th District Councilwoman Helen Holton, from the city.
"Nobody knows if we're city or county," said Christian, who lives on Medwick Garth East. "Both parties need to be helpful here. It can't be just one or the other."
Christian admitted he is at the head of this project despite knowing that he and his wife, Michelle, may not be residents of the community much longer.
A student in the College of Notre Dame of Maryland's Leadership in Teaching master's degree program, Christian is unsure of where he will end up next.
Once the C.O.P. gets off the ground, Christian said he wants to hear the concerns of his neighbors.
"We know more or less what the problems are, but I know there are people in this community that want to say something," said Christian, a Spanish teacher at Our Lady of Good Counsel in Baltimore.
Once the concerns are heard, Christian said the group will begin assigning roles and assigning areas of responsibility.
"It's an immediate demand for the community," Christian said.
"We feel like our neighborhood is something worth defending."
2011年4月20日星期三
Musculoskeletal News Roundup 21-Apr-11
Centinel Spine announced that 1Q:11 sales increased by 47% over the year-ago period. The company named adoption of the STALIF TT interbody device, which is intended for use in anterior lumbar surgery, and the STALIF C, which is intended for cervical indications, among the growth drivers.
Johnson & Johnson reported 1Q:11 sales of $16.2 billion, up 2% over the year-ago period and beating estimates by $356.9 million. Listed among a number of growth drivers were DePuy's sports medicine business. DePuy contributed $1.5 billion to sales, up 2% over 1Q:10. As discussed on the earnings call, hip sales declined by 2%, and knee was down by 4%. Spine was up by 1%. Growth rates exclude the effects of currency. Adjusted net earnings for 1Q:11 were $3.7 billion, or $1.35 per share, up 5% over the year-ago period and beating estimates by $0.09 per share.
Stryker reported 1Q:11 sales of $2.0 billion, up 10% over the year-ago period and beating estimates by $13.4 million. Recon sales were flat at $911.0 million, which the company attributed to lower shipments in knee and unnamed other implant systems offsetting higher shipments in hip and trauma and extremities. Among recon segments, hip was up 2%; knee was down 2% and trauma and extremities was up 2%. Spine and neuro sales contributed $340.3 million to total revenues, up 4% organically over the year-ago period. Spine sales were up 1% to $161.6 million. Growth rates exclude the effects of currency. Adjusted net earnings for the quarter were $322.0 million, or $0.90 per share, up 13% over the year-ago period and beating estimates by a penny.
Funding
AOI Medical raised $2.9 million of a planned $5.6 million funding round. The company is developing the Ascendx device for the treatment of vertebral compression fractures.
Benvenue Medical raised $35.5 million in a Series C round of financing co-led by new investors Domain Associates and Technology Partners, who were joined by current investors Versant Ventures and DeNovo Ventures. The proceeds will be used to complete KAST (Kiva System as a Vertebral Augmentation Treatment - A Safety and Effectiveness Trial) and execute on the company's commercialization strategy in the U.S. and Europe. The company says KAST, which is being conducted in support of a 510(k) submission, is the "largest randomized study versus balloon kyphoplasty to date." The Kiva system consists of a PEEK-OPTIMA cylindrical implant that is inserted in a continuous loop fashion; bone cement is delivered through the implant's lumen and into the vertebral body.
Carmell Therapeutics raised a Series A financing led by Harbor Light Capital Partners, who were joined by Newlin Investment Company, the PLSG Accelerator Fund, LLC, Innovation Works, Ariel Savannah Angels, Blue Tree Allied Angels and individual investors. The company will use the funds to establish a pilot manufacturing facility and collect data on the company's platelet-rich plasma products. The company says their materials incorporate both platelet and plasma-derived regenerative factors and are "sterile, ready-to-use, easy to handle, shape and suture and exhibit mechanical properties designed to match the repaired tissue."
Regulatory
StelKast received FDA 510(k) clearance for their EXp Acetabular Liners, which are comprised of antioxidant and highly cross-linked polyethylene technology. The company plans to launch the EXp Acetabular System in July.
Product Introduction and Update
Medtronic launched the MARROWMAX Bone Marrow Aspiration Needle Kit. The product features a multi-holed cannula, which "allows for simultaneous marrow draws at the same position thereby reducing aspiration time and the need for sometimes painful repositioning of the needle."
Legal
Genzyme filed a patent infringement suit against Seikagaku and a Zimmer subsidiary that distributes Seikagaku's HA products in the U.S. The suit alleges that Seikagaku's HA technology, recently approved in the U.S. by the FDA and branded Gel-One, infringes patents for Synvisc.
Collaborations
RTI Biologics signed an agreement to provide spinal allograft implants to Alphatec Spine. Under the agreement, which is effective immediately and has a three-year term with the option to renew, RTI will process allograft implants for use in spine and made from assembled cortical allograft.
Johnson & Johnson reported 1Q:11 sales of $16.2 billion, up 2% over the year-ago period and beating estimates by $356.9 million. Listed among a number of growth drivers were DePuy's sports medicine business. DePuy contributed $1.5 billion to sales, up 2% over 1Q:10. As discussed on the earnings call, hip sales declined by 2%, and knee was down by 4%. Spine was up by 1%. Growth rates exclude the effects of currency. Adjusted net earnings for 1Q:11 were $3.7 billion, or $1.35 per share, up 5% over the year-ago period and beating estimates by $0.09 per share.
Stryker reported 1Q:11 sales of $2.0 billion, up 10% over the year-ago period and beating estimates by $13.4 million. Recon sales were flat at $911.0 million, which the company attributed to lower shipments in knee and unnamed other implant systems offsetting higher shipments in hip and trauma and extremities. Among recon segments, hip was up 2%; knee was down 2% and trauma and extremities was up 2%. Spine and neuro sales contributed $340.3 million to total revenues, up 4% organically over the year-ago period. Spine sales were up 1% to $161.6 million. Growth rates exclude the effects of currency. Adjusted net earnings for the quarter were $322.0 million, or $0.90 per share, up 13% over the year-ago period and beating estimates by a penny.
Funding
AOI Medical raised $2.9 million of a planned $5.6 million funding round. The company is developing the Ascendx device for the treatment of vertebral compression fractures.
Benvenue Medical raised $35.5 million in a Series C round of financing co-led by new investors Domain Associates and Technology Partners, who were joined by current investors Versant Ventures and DeNovo Ventures. The proceeds will be used to complete KAST (Kiva System as a Vertebral Augmentation Treatment - A Safety and Effectiveness Trial) and execute on the company's commercialization strategy in the U.S. and Europe. The company says KAST, which is being conducted in support of a 510(k) submission, is the "largest randomized study versus balloon kyphoplasty to date." The Kiva system consists of a PEEK-OPTIMA cylindrical implant that is inserted in a continuous loop fashion; bone cement is delivered through the implant's lumen and into the vertebral body.
Carmell Therapeutics raised a Series A financing led by Harbor Light Capital Partners, who were joined by Newlin Investment Company, the PLSG Accelerator Fund, LLC, Innovation Works, Ariel Savannah Angels, Blue Tree Allied Angels and individual investors. The company will use the funds to establish a pilot manufacturing facility and collect data on the company's platelet-rich plasma products. The company says their materials incorporate both platelet and plasma-derived regenerative factors and are "sterile, ready-to-use, easy to handle, shape and suture and exhibit mechanical properties designed to match the repaired tissue."
Regulatory
StelKast received FDA 510(k) clearance for their EXp Acetabular Liners, which are comprised of antioxidant and highly cross-linked polyethylene technology. The company plans to launch the EXp Acetabular System in July.
Product Introduction and Update
Medtronic launched the MARROWMAX Bone Marrow Aspiration Needle Kit. The product features a multi-holed cannula, which "allows for simultaneous marrow draws at the same position thereby reducing aspiration time and the need for sometimes painful repositioning of the needle."
Legal
Genzyme filed a patent infringement suit against Seikagaku and a Zimmer subsidiary that distributes Seikagaku's HA products in the U.S. The suit alleges that Seikagaku's HA technology, recently approved in the U.S. by the FDA and branded Gel-One, infringes patents for Synvisc.
Collaborations
RTI Biologics signed an agreement to provide spinal allograft implants to Alphatec Spine. Under the agreement, which is effective immediately and has a three-year term with the option to renew, RTI will process allograft implants for use in spine and made from assembled cortical allograft.
订阅：
博文 (Atom)